• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

byArnav Agarwal, MDandAliya Ramjaun
September 25, 2019
in Chronic Disease, Neurology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A shortened course of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer was associated with decreased peripheral sensory neuropathy without compromising effectiveness.

Evidence Rating Level: 1 (Excellent)

FOLFOX4 regimen, which includes oxaliplatin, has proven efficacy in both the metastatic colorectal cancer setting and the adjuvant setting for resected stage III colon cancers. Peripheral neuropathy is a debilitating associated side effect of oxaliplatin-based chemotherapy. The objective of the ACHIEVE trial was to evaluate the effectiveness and safety of a shortened course of adjuvant oxaliplatin-based chemotherapy in patients with stage III colon cancer. In this open-label multicenter randomized phase III non-inferiority trial based in Japan, 1,313 patients were randomly assigned to receive either 6 months or 3 months of adjuvant chemotherapy with mFOLFOX6 or CAPOX (at physician’s discretion). Treatment regimens were repeated every two weeks for a maximum of 12 or 6 cycles, respectively. The primary efficacy endpoint was disease-free survival, and secondary endpoints included peripheral sensory neuropathy for up to 3 years and overall survival. Of 1,291 treated patients, 969 (75%) of participants received the CAPOX regimen. Researchers found that disease-free survival with 3-month therapy was not significantly different when compared to 6-month therapy (HR 0.95, 95% CI 0.76 to 1.20). The rate of any grade of peripheral neuropathy was 9.7% with 3-month therapy and 24.3% with 6-month therapy (p<0.001), with significantly lower incidences with CAPOX therapy than with mFOLFOX therapy with both durations. The findings of this study therefore indicate that a shorter duration of therapy (3 months) with oxaliplatin-containing chemotherapy may confer significantly lower rates of peripheral sensory neuropathy without compromised effectiveness.

Click to read the study in JAMA Oncology

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer

Diabetic polyneuropathy observed to have dynamic changes overtime

#VisualAbstract: Increased Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy Risk Among Patients with Diabetes

Tags: CAPOXcolon cancerFOLFOX4neuropathyoxaliplatin
Previous Post

Daily aspirin may benefit some patients without existing cardiovascular disease

Next Post

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

RelatedReports

#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
StudyGraphics

#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer

June 13, 2025
Chronic Disease

Diabetic polyneuropathy observed to have dynamic changes overtime

May 21, 2025
#VisualAbstract: Increased Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy Risk Among Patients with Diabetes
StudyGraphics

#VisualAbstract: Increased Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy Risk Among Patients with Diabetes

April 18, 2025
#VisualAbstract: Invitation to Fecal Immunochemical Test is Noninferior to Colonoscopy Screening in Colorectal Cancer Mortality
StudyGraphics

#VisualAbstract: Invitation to Fecal Immunochemical Test is Noninferior to Colonoscopy Screening in Colorectal Cancer Mortality

April 7, 2025
Next Post
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

General anesthesia exposure in infants not linked to impaired cognitive development

Early revascularization improves survival in patients with ischemia demonstrated on positron emission tomography perfusion imaging

Insulin costs rose exponentially, regardless of formulation or patent

Insulin discontinuation among patients over 75 more common in healthier patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.